A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
NCT05418387 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2024-11-25
Summary
This project will develop and pilot test social support intervention for an underserved population, Hispanics in Arizona, who have high rates of kidney and liver cancer to improve health equity. The investigators will incorporate caregivers (family members) and other individuals in a patient's social network in survivorship, who are especially critical to quality cancer care. Caregivers provide more than half the care to cancer survivors and are often instrumental in facilitating the survivor to receive the care needed and adhere to guidelines. Through this project, the investigators will be able to leverage the resources of the Cancer Heath Equity Research Center (e.g., community outreach) to develop an intervention that has the potential for scalability and reach and recruit a sufficient sample across the target catchment area (including rural participants who may live near the US-Mexico border).
Conditions
Interventions
- BEHAVIORAL
-
Social Support Network Intervention
The navigator will provide basic patient navigation services and Supportive Health Education to the patient/caregiver dyads in the patient's preferred language using the Support Network Workbook. The intervention will consist of 7 telephone sessions. There will be 2 sessions in the first month and one session per month after the first month (6 months total). Coaching and guiding techniques rather than lectures will be used applying dyads' specific social support network information. Each session will be about 30 minutes long.
- BEHAVIORAL
-
Control (Patient Navigation Service)
The patient navigator will provide basic patient navigation services consisting of health care barriers/social needs assessment, referral to social workers (if eligible) and support groups for patients and caregivers, and transportation assistance without Supportive Health Education. Patient/caregiver dyads in the control group will be contacted at 3- and 6-months post-enrollment and asked about their experience receiving treatment, any challenges they encountered or are currently facing, and the care support they received from family members, friends, CHWs, and health care providers.
Sponsors & Collaborators
-
American Cancer Society, Inc.
collaborator OTHER -
University of Arizona
lead OTHER
Principal Investigators
-
Ken Batai, PhD · University of Arizona
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-09-30
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
More Related Trials
-
Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis
NCT00767468 ·Status: TERMINATED ·Phase: PHASE1
-
Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma
NCT06138769 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
NCT05168163 ·Status: RECRUITING ·Phase: PHASE2
-
A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection
NCT02650427 ·Status: COMPLETED ·Phase: PHASE1
-
Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial
NCT04687163 ·Status: UNKNOWN ·Phase: PHASE3
-
Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
NCT03722498 ·Status: WITHDRAWN ·Phase: PHASE2
-
STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention
NCT03706742 ·Status: COMPLETED ·Phase: NA
-
Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection
NCT05546619 ·Status: UNKNOWN ·Phase: NA
-
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
NCT03755791 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
NCT02748304 ·Status: TERMINATED ·Phase: NA
-
HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC
NCT03812783 ·Status: UNKNOWN ·Phase: PHASE2
-
HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
NCT03780634 ·Status: WITHDRAWN ·Phase: PHASE2
-
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT01004978 ·Status: COMPLETED ·Phase: PHASE3
-
Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies
NCT05803928 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Pembrolizumab and Radiotherapy in Liver Cancer
NCT03316872 ·Status: TERMINATED ·Phase: PHASE2
-
HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
NCT03803254 ·Status: WITHDRAWN ·Phase: PHASE2
-
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
NCT06505486 ·Status: RECRUITING
-
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
NCT02733809 ·Status: UNKNOWN ·Phase: PHASE4
-
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
NCT02989870 ·Status: WITHDRAWN ·Phase: PHASE1
-
Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.
NCT02971696 ·Status: COMPLETED ·Phase: PHASE3
-
Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
NCT03838796 ·Status: UNKNOWN ·Phase: NA
-
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
NCT02323906 ·Status: TERMINATED ·Phase: PHASE1
-
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
NCT02575339 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC
NCT05007587 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
NCT03713593 ·Status: COMPLETED ·Phase: PHASE3